MET and cancer: Altogether, piperlongumine can be considered as a promising anti-cancer bioactive agent that acts through the downregulation of c-Met, STAT3, NF-κB, PI3K/Akt, and ERK/MAPK signaling pathways, inhibition of GSTP1, and upregulation of hTRPV2.